A topical microemulsion for the prevention of allergic rhinitis symptoms: results of a randomized, controlled, double-blind, parallel group, multicentre, multinational clinical trial (Nares study) by Ojeda, Pedro et al.
ALLERGY, ASTHMA & CLINICAL 
IMMUNOLOGY
Ojeda et al. Allergy, Asthma & Clinical Immunology 2013, 9:32
http://www.aacijournal.com/content/9/1/32RESEARCH Open AccessA topical microemulsion for the prevention of
allergic rhinitis symptoms: results of a
randomized, controlled, double-blind, parallel
group, multicentre, multinational clinical trial
(Nares study)
Pedro Ojeda1*, Núria Piqué2, Alicia Alonso3, Julio Delgado4, Francisco Feo5, Juan Manuel Igea6, Ana Navarro7,
José María Olaguibel8, Javier Subiza9, Carles Nieto10 and Morgan Andersson11Abstract
Background: Since barrier protection measures to avoid contact with allergens are being increasingly developed,
we assessed the clinical efficacy and tolerability of a topical nasal microemulsion made of glycerol esters in patients
with allergic rhinitis.
Methods: Randomized, controlled, double-blind, parallel group, multicentre, multinational clinical trial in which
adult patients with allergic rhinitis or rhinoconjunctivitis due to sensitization to birch, grass or olive tree pollens
received treatment with topical microemulsion or placebo during the pollen seasons. Efficacy variables included
scores in the mini-RQLQ questionnaire, number and severity of nasal, ocular and lung signs and symptoms, need
for symptomatic medications and patients’ satisfaction with treatment. Adverse events were also recorded.
Results: Demographic characteristics were homogeneous between groups and mini-RQLQ scores did not differ
significantly at baseline (visit 1). From symptoms recorded in the diary cards, the ME group showed statistically
significant better scores for nasal congestion (0.72 vs. 1.01; p = 0.017) and mean total nasal symptoms
(0.7 vs. 0.9; p = 0.045). At visit 2 (pollen season), lower values were observed in the mini-RQLQ in the ME group,
although there were no statistically significant differences between groups in both full analysis set (FAS) and
patients completing treatment (PPS) populations. The results obtained in the nasal symptoms domain of the
mini-RQLQ at visit 2 showed the highest difference (−0.43; 95% CI: -0.88 to 0.02) for the ME group in the FAS
population. The topical microemulsion was safe and well tolerated and no major discomforts were observed.
Satisfaction rating with the treatment was similar between the groups.
Conclusions: The topical application of the microemulsion is a feasible and safe therapy in the prevention of
allergic symptoms, particularly nasal congestion.
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In the management of allergy, there are four general
principles: patient education, avoidance of allergens/
triggering factors, use of appropriate pharmacotherapy
and immunotherapy [1,2]. Importantly, allergen avoidance
should be indicated when possible and should be an
integral part of the management strategy, according to the
clinical and practical recommendations of ARIA guidelines
for the management of allergic rhinitis [2,3].
With regard to allergen avoidance or modification of
allergen exposure, barrier protection measures for avoiding
contact with allergens, such as nose filters or nasally applied
cellulose powders, are being increasingly developed and
evaluated in patients with allergic rhinitis [4]. In this con-
text, a topical microemulsion made of glycerol esters for
topical application in the nose has been developed, with the
aim of conferring a protective effect in patients with allergic
rhinitis. Its mechanism of action consists of creating a lipid
coating that spreads over the surface of the nasal mucosa.
Acting this way, the protective effect is achieved by creating
a lipid barrier that prevents allergens being deposited onto
the nasal mucosa and reaching the specific IgE of the mu-
cosal immune system cells and engulfing allergens already
present in the nasal mucosa. As such, the allergic reaction
will be blocked by the application of the microemulsion
at the very beginning of the allergic cascade, in contrast
to commonly used symptomatic medications such as
antihistamines or corticosteroids, which act at the end
of this cascade.
Previous studies have shown that the application of
the topical microemulsion caused a reduction of nasal
symptoms scores during one week of treatment in symp-
tomatic patients with perennial allergic rhinitis due to
house dust mites [5]. In a single-blind, placebo-controlled,
crossover study, a reduction in nasal symptoms scores and
a drop in a2-macroglobulin levels in nasal lavage fluid,
indicative of attenuation of inflammation, were also
observed after challenge with pollen allergen in patients
with allergic rhinitis [6].
In this study, which included patients with seasonal
allergic rhinitis, the effect of a topical microemulsion
was examined in a natural allergen exposure setting
(during birch, grass, and olive tree pollen seasons). The
intervention was given according to a placebo-controlled,
double-blind, randomized, parallel group design in nine
study centres in Spain and Sweden. Rhinitis-specific quality
of life and symptoms characteristic of seasonal allergic rhin-
itis were monitored throughout the pollen season. We re-
port on the symptom-reducing effects of the intervention.
Methods
The study protocol was approved by the Ethics Committee
of Human Experimentation in Spain and Sweden and
procedures were in accordance with the ethical standardslaid down in the Declaration of Helsinki, as revised in the
year 2000. Written informed consent was obtained from
all subjects. Patients were recruited in one Swedish centre
(n = 22) and in 8 Spanish centres (n = 88), with a varied
geographical distribution in order to cover the different
pollination patterns.
This randomized, controlled, double-blind, parallel
group, multicentre, multinational clinical trial (8 centres
in Spain and 1 in Sweden) was performed to evaluate
the efficacy and tolerability of the topical microemulsion
(ME group) compared to a normal saline solution
(SS group) in adult patients with moderate to severe allergic
rhinitis or rhinoconjunctivitis due to sensitization to
grass, birch, or olive tree pollens. The diagnosis was
made according to the investigators’ judgment based
on the clinical picture correlated with positive skin
prick tests (wheal diameter ≥ 3 mm) and/or specific IgE
(titer ≥ 0.35 kU/L) for the allergenic extracts under
consideration and routinely used by the investigators in
their clinical practice. Potential participants were excluded
if they had asthma of any origin, seasonal rhinitis with
negative allergy testing, had received allergen-specific
immunotherapy within the previous 36 months, or were
on systemic corticosteroids or other immunosuppressant
or immunomodulatory drugs.
The patients were randomly assigned to receive
the microemulsion (ME group) or the saline solution
(SS group). The demographic characteristics are shown in
Table 1. The composition of the topical microemulsion
was glycerol monooleate, propylene glycol, polyethylene
glycol 400, sesame oil, polysorbate 80, sodium chloride
0.9%, menthol, eucalyptus oil and water, whereas the
placebo was composed of sodium chloride 0.9%, menthol,
eucalyptus oil and water at a neutral pH. Both products
were manufactured by Reig Jofré (Reig Jofré Group S.A.,
Barcelona, Spain), according to international Good
Manufacturing Practices. Treatment (one puff of either
product b.i.d. per nostril, in the early morning and at
midday) was administered throughout the expected
dates of the pollen seasons for the pollens considered in
this study. The pollen periods were defined according to
the pollen counts provided by local agencies or networks,
from the start of significant pollen counts until the end of
significant pollen counts. Three visits were performed: just
before the beginning (visit 1), in the middle (visit 2) and at
the end of the pollen season (visit 3).
At each visit, the investigators performed a physical
examination on each subject indicating the presence or
absence of the following symptoms: rhinorrhea, nasal
edema, nasal mucosa pallor, nasal crusts, eye redness,
epiphora, conjunctival secretion, prolonged expiration,
rhonchi or wheezing, and tachypnea. The participants
completed a mini-RQLQ questionnaire (7, 8). At visit 1,
the patients were provided with a daily symptoms and
Table 1 Baseline demographic characteristics of the study subjects
Statistic variable ME group SS group
Gender (M / F) n (%) 28 (58.8) / 25 (47.1) 25 (48.0) / 27 (51.9)
Age (years) Mean (SD) 32.6 (9.9) 34.9 (11.5)
Range 18.0 - 57.0 18.0 – 69.0
Duration of rhinitis (years) Median (IQR) 11.0 (9.0) 10.0 (13.0)
Range 1.0 - 33.0 1.0 - 47.0
Sensitization profile % of subjects testing positive at SPT
Grass pollen 84.6 92.4
Olive tree pollen 46.1 52.8
Birch tree pollen 25.0 22.6
SPT Skin Prick Test, SD Standard Deviation, IQR Interquartile range.
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every day, at the end of the day, from visit 1 to visit 3.
The severity of nasal symptoms (itching, runny nose,
sneezing, and nasal congestion) and ocular symptoms
(itching, redness, and tearing) was scored according to
the following scale: 0 = no symptoms; 1 =mild symptoms;
2 =moderate symptoms; 3 = severe symptoms, based on
the patient’s opinion. The patients were allowed to take
topical antihistamines or corticosteroids, as well as com-
mercially available oral antihistamines on an on-demand
basis and according to the prescriptions made by the in-
vestigators. The brands as well as the number of times
used per day were recorded on the dairy. Adverse events
were recorded at visits 2 and 3, and a questionnaire on the
patient’s satisfaction with the treatment was completed
at visit 3 (very satisfied; neither satisfied nor dissatisfied;
dissatisfied; very dissatisfied).
The primary efficacy variable was the overall allergic
rhinitis-related quality of life calculated by the least-
squares mean of global scores in the self-administered
mini-RQLQ questionnaire at visit 2 in the FAS popula-
tion (randomized patients meeting all selection criteria
and having a mini-RQLQ value at baseline). Secondary
efficacy variables included: mini-RQLQ scores at visits 2
and 3 in the FAS (full analysis set) and PPS populations
(FAS patients who completed the study treatment, did
not take prohibited medications and had a value for the
primary variable); number of nasal, ocular and lung signs
(from the physical examination); severity of nasal and
ocular symptoms, measured as the mean of nasal symp-
toms and of ocular symptoms (the sum of nasal symptoms
divided by 4; the sum of ocular symptoms divided by 3;
range: 0–3); need for symptomatic medications; adherence
(based on the medication returned by subjects); and the
patient’s satisfaction with treatment.
Descriptive statistics were used for each outcome and
intra and inter-group comparisons were made. Two-sided
p-values were obtained and statistically significant resultswere declared if p < 0.05. The 95% confidence intervals
were computed for the treatment effect, using either least-
squares mean difference or Hodges-Lehmann estimators.
ANCOVA analysis was considered in appropriate cases and
a Mantel-Haenszel Chi-square test was also performed.
The statistical significance level was calculated at two-sided
and one-sided p values. Homogeneity of association across
centres was assessed by the Breslow-Day test.
Results
A total of 110 patients were included in the study database
(n = 55 in each treatment group). Figure 1 shows the study
retention data.
The study duration (period between visits 1 and 3)
ranged from 29 to 133 days, depending on the duration
of the pollen season in the different geographical areas.
Demographic characteristics were homogeneous between
groups, as were the duration of allergic rhinitis and the
sensitization profiles (Table 1). Rhinorrhea, edema of the
nasal mucosa, nasal mucosa pallor and crusts, eye redness
and epiphora were seldom present at baseline in both
groups and these findings significantly increased in both
groups at visit 2.
In general, efficacy results were favorable for the
microemulsion. The least-squares means for the allergic
symptoms recorded in the patients’ diary cards were always
lower in the active group than in the control group, in
both FAS (full analysis set) and PPS (per protocol set)
populations. In this respect, statistically significant dif-
ferences were detected in the FAS population for nasal
congestion (p = 0.011), while the difference in mean scores
for nasal symptoms did not reach statistical significance
(p = 0.068). In the PPS population, significant differences
were found for nasal congestion (p = 0.017) and mean
nasal symptoms (one-sided p = 0.044) (Figure 2).
Lower global scores in the mini-RQLQ at visit 2 in the
FAS population, which was the primary efficacy variable,
were also observed in the group of patients treated with the
Assessed for eligibility (n = 110)
Excluded (n = 1)
Declined to participate (n = 1)
ME Group (n = 54)
Received topical microemulsion (n = 52)
Did not receive topical microemulsion
(violation of one or more entry criteria
reasons) (n = 2)
FAS Population
Lost to follow-up (missing value of the 
miniRQLQ or non-completion of the 
study treatment as planned) (n = 16)
Lost to follow-up (missing value of the 
miniRQLQ or non-completion of the 
study treatment as planned) (n = 12)
Analysed (n = 43)
PPS Population
Analysed (n = 39)
PPS Population
SS Group (n = 55)
Received saline solution (n = 53)
Did not receive saline solution
(violation of one or more entry criteria
reasons) (n = 2)
FAS Population
Safety set Population
Randomized (n = 109)
Figure 1 Flow diagram of the clinical trial progress. Safety Set (SS): Randomized patients who took at least one dose of the study treatment;
Full Analysis Set (FAS): randomized patients who met all selection criteria and had a value of the mini-RQLQ at baseline (visit 1); Per Protocol Set
(PPS): FAS patients who completed the study treatment, did not take prohibited medications and who had a value for the primary variable
(mini-RQLQ at visit 2).
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(Figure 3), although without reaching statistically significant
differences between the groups.
In both populations and at both visits, least-squares
means of the global and single dimension scores in the
mini-RQLQ were also lower in the active than in the
control group (except for activity limitations at visit 3)
(Figure 3).
Of note, results obtained in the nasal symptoms domain
of the mini-RQLQ at visit 2 showed the highest difference
(−0.43; 95% CI: -0.88 to 0.02, p = 0.059) in the FAS popu-
lation. The scores obtained at visit 2 were higher than at
visit 3, thus indicating a better quality of life at the end of
the study, which corresponded to the end of the pollen
season and was in agreement with the reported incidence
of allergic symptoms (Figure 3).Correspondingly, nasal signs recorded at the physical
examination were more frequent in the control group
at both visits, with RR values below 1. Eye signs were
also more frequent at visit 3 in the control group
(with RR = 0.42) but more frequent in the active group at
visit 2 (RR = 1.45). No patients of any group presented
lung signs at visit 2 and only one patient in the active
group presented lung signs at visit 3.
The distribution of satisfaction scores was similar in
both treatment groups (with no statistically significant
differences), thus indicating no major discomfort from the
application of the microemulsion. Importantly, proportions
of patients taking corticosteroids were higher in the control
group than in the group treated with the microemulsion,
although differences were not statistically significant
(RR > 1.19; 95%CI 0.67-2.11; p = 0.538). Based on the
Allergic symptoms from the patient´s diary (FAS population)
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Figure 2 Allergic symptoms. Allergic symptoms recorded in the patient’s diary as daily means (FAS and PPS populations).
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herence to treatment was high (93% in the active and
92% in the control group).
The application of the topical microemulsion was
safe and well tolerated, with only 3 events considered
as definitely related to the microemulsion treatment
(intense nasal and palatal itching/nasal itching and
rhinorrhea/nasal irritation) and 8 events considered as pos-
sibly related (sneezing, pharyngeal discomfort, pharyngeal
itching and bitterness, nasal itching and rhinorrhea). Only
one event in the active group resulted in temporary discon-
tinuation of the study treatment and two events in the con-
trol group resulted in definitive withdrawal. Importantly,
during the study, no serious adverse events occurred and
most adverse events reported in both groups were relatedwith the allergic rhinitis pathology, in the form of nasal and
respiratory symptoms.
Discussion
In this study, which included patients with allergic rhinitis
caused by birch, grass, and olive pollen allergen, we showed
that topical/intranasal administration of small volumes
of a microemulsion twice daily during the pollen season
reduces overall nasal symptoms compared with placebo
(i.e. isotonic saline). This observation is of relevance in
terms of how allergen avoidance can be achieved and how
microemulsions may be used as a treatment for seasonal
allergic rhinitis.
This randomized, controlled, double-blind, parallel
study was performed according to the international
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Figure 3 Patient’s quality of life. Results of quality of life, global and in the different dimensions of the mini-RQLQ questionnaire
(FAS and PPS population).
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gic rhinitis [3] and with a similar design to other studies
evaluating allergen avoidance strategies [4,6]. Quality of
life is an important treatment efficacy marker in patients
with allergic diseases [7] and in our study, the effect of the
microemulsion was assessed using the validated and reliable
mini-RQLQ questionnaire [8], commonly used in patients
with rhinitis and/or rhinoconjunctivitis [7,8].
Symptoms of allergic rhinitis recorded throughout the
pollen season in the placebo group indicated that inten-
sity was mild, reaching a score of 0.90 on a scale from 0
to 3 for total nasal symptoms. In patients who receivedthe microemulsion intervention, least squares means of
all variables derived from symptoms were nevertheless
always lower compared with placebo, and this pattern
reached statistical significance for total nasal symptoms.
Accordingly, we suggest that topical/intranasal administra-
tion of small volumes of a microemulsion may be viewed as
a preventive measure or treatment option in seasonal aller-
gic rhinitis. This conclusion may be strengthened by the
fact that the present comparator, i.e. isotonic saline, may
not be a true placebo since isotonic (and hypertonic) saline
may be effective in allergic rhinitis. For example, Garavello
et al. showed that nasal administration of isotonic saline
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rhinitis [9]. The possibility that saline may exert such
an effect, in combination with the significant difference
between the microemulsion and isotonic saline in this
study, underscores that the microemulsion is effective
in seasonal allergic rhinitis.
In contrast to our previous study in seasonal allergic
rhinitis in which a pool-device was used for experimental
administration of a large volume of microemulsion [5], this
study involved repeated administration of a small volume
(50 μl) using a spray-like device. Symptoms were recorded
in the evening, i.e. at time points up to 6–8 hours after dos-
ing. The results therefore suggest that the microemulsion,
given in small doses, was effective for many hours.
Similarly, an extended effect was also suggested in our
previous study of patients with perennial allergic rhinitis
who received low-dose microemulsion intervention [6].
Microemulsions containing glycerol monooleate are
known to be bioadhesive and are probably not cleared
by mucociliary activity as rapidly as, for example, sus-
pensions [10]. This may explain why a small volume of
microemulsion is sufficient for reducing symptoms in
seasonal allergic rhinitis. However, further studies involving
somewhat larger volumes and more frequent dosing may
be considered to see if greater symptom-reducing effects
can be achieved. Also, such studies should include compari-
sons with established treatments for allergic rhinitis includ-
ing antihistamines and topical corticosteroids.
The findings in this study are in agreement with our
previous observations on symptom-relieving effects in
allergic rhinitis and support the hypothesis that the
microemulsion reduces the interaction between the al-
lergen and the mucosa in a non-specific fashion [5,6].
Accordingly, we suggest that microemulsions may be
efficacious for allergic rhinitis regardless of the type of
allergen producing the nasal symptoms. Indeed, interven-
tions aiming at avoiding allergen exposure or decreasing al-
lergen exposure in general have recently received attention.
A gel-forming cellulose powder was shown to reduce res-
cue medication use in a seasonal allergen exposure setting
[4,11,12]. Furthermore, symptoms were reduced by cellu-
lose powder in an experimental challenge model involving
dust mite allergens [13]. Taken together, the above concepts
highlight the possibility that devices aiming at physically
protecting the nasal mucosa against allergens may be valid
treatment options in allergic rhinitis. This may be viewed
as being in line with current recommendations of allergen
avoidance in allergic rhinitis [3].
Conclusions
We conclude that the topical application of the
microemulsion reduces symptoms of seasonal rhinitis in a
natural allergen exposure setting. Our finding suggests that
topical microemulsions may be a useful option for avoidingmucosal exposure to allergens in this pathological con-
dition. We suggest that microemulsions may be viewed
as a means of reducing mucosal exposure to harmful
inhaled factors in general.
Abbreviations
ANCOVA: Analysis of covariance; ARIA: Allergic Rhinitis and its Impact on
Asthma; b.i.d: Twice a day; FAS: Full analysis set; IgE: Immunoglobulin E;
ME: Microemulsion; PPS: Per protocol set; RQLQ: Rhinoconjunctivitis quality
of life questionnaire; RR: Relative risk; SS: Saline solution.
Competing interests
Pedro Ojeda received honoraria from Reig Jofré for the design and study
direction. Carlos Nieto is Medical Director of Reig Jofré. Morgan Andersson
received financial support from Reig Jofré for the conduction of the study.
Morgan Andersson holds patents pertinent to the microemulsion used in
this study. Núria Piqué received honoraria from Reig Jofré to write the article.
Authors’ contributions
Study conception and design: PO and MA. Study conduct: PO, MA, AA, JD,
FF, JMI, AN, JMO, JS. Data analysis: PO. Contribution of reagents/materials/
analysis tools: PO, CN. Article writing: PO, NP, MA. All authors read and
approved the final manuscript.
Acknowledgement
Our gratitude to Albert Cobos who performed the statistical analysis.
Funding
Reig Jofré Group, S.A., Barcelona, Spain.
Author details
1Clínica de Asma y Alergia Dres, Ojeda, Oquendo, 23, 20006 Madrid, Spain.
2Department of Microbiology and Parasitology, Pharmacy Faculty, Universitat
de Barcelona, Av. Joan XXIII, 31, 08028 Barcelona, Spain. 3Clínica Paracelso
Médico Quirúrgica, General Ruiz, 4, 47004 Valladolid, Spain. 4Department of
Allergy, University Hospital Virgen Macarena, Av. Dr. Fedriani, 3, 41071 Seville,
Spain. 5Department of Allergy, University Hospital of Ciudad Real, Obispo
Rafael Rorija, 13005 Ciudad Real, Spain. 6Alergoasma Clinic, Pinto, 2-18, 37001
Salamanca, Spain. 7Hospital Nuestra Señora de Balme, Ambrosio de la Cuesta,
11, Seville, Spain. 8Allergy Department, Complejo Hospitalario de Navarra,
Irunlarrea, 3, 31008 Pamplona, Spain. 9Clínica Subiza de Asma y Alergia,
General Pardinas, 116, 28006 Madrid, Spain. 10Reig Jofré Group, S.A., Gran
Capità, 6, 08970 Sant Joan Despí, Barcelona, Spain. 11Department of
Otorhinolaryngology, Head & Neck Surgery, Skåne University Hospital, Ole
Römers väg, 3, 22363 Lund, Sweden.
Received: 14 April 2013 Accepted: 25 July 2013
Published: 27 August 2013
References
1. Mandhane SN, Shah JH, Thennati R: Allergic rhinitis: an update on disease,
present treatments and future prospects. Int Immunopharmacol 2011,
11:1646–1662.
2. Willsie SK: Improved strategies and new treatment options for allergic
rhinitis. J Am Osteopath Assoc 2002, 102:S7–S14.
3. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB,
van Wijk RG, Ohta K, Zuberbier T, Schünemann HJ: Global Allergy and
Asthma European Network; Grading of Recommendations Assessment,
Development and Evaluation Working Group. Allergic Rhinitis and its
Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol
2010, 126:466–476.
4. Åberg N, Dahl Å, Benson M: A nasally applied cellulose powder in
seasonal allergic rhinitis (SAR) in children and adolescents; reduction of
symptoms and relation to pollen load. Paediatric Allergy Immunol 2011,
22:594–599.
5. Andersson M, Greiff L, Wollmer P: Nasal treatment with a microemulsion
reduces allergen challenge-induced symptoms and signs of allergic
rhinitis. Acta Otolaryngol 2008, 128:666–669.
Ojeda et al. Allergy, Asthma & Clinical Immunology 2013, 9:32 Page 8 of 8
http://www.aacijournal.com/content/9/1/326. Andersson M, Greiff L, Wollmer P: Effects of a topical microemulsion in
house dust mite allergic rhinitis. Basic Clin Pharmacol Toxicol 2011,
108:146–148.
7. Valero A, Alonso J, Antépara I, Baró E, Colás C, del Cuvillo A, Ferrer M,
Herdman M, Marti-Guadaño E, Monclús L, Navarro-Pulido AM, Sastre J,
Izquierdo I, Mullol J: Health-related quality of life in allergic rhinitis:
comparing the short form ESPRINT-15 and MiniRQLQ questionnaires.
Allergy 2007, 62:1372–1378.
8. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN: Development and
validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire.
Clin Exp Allergy 2000, 30:132–140.
9. Garavello W, Romagnoli M, Gaini RM: Hypertonic or isotonic saline for
allergic rhinitis in children. Pediatr Allergy Immunol 2005, 16:91–92.
10. Nielsen LS, Schubert L, Hansen J: Bioadhesive drug delivery systems. I.
Characterisation of mucoadhesive properties of systems based on glyceryl
mono-oleate and glyceryl monolinoleate. Eur J Pharm Sci 1998, 6:231–239.
11. Josling P, Steadman S: Use of cellulose powder for the treatment of
seasonal allergic rhinitis. Adv Ther 2003, 20:213–219.
12. Emberlin JC, Lewis RA: A double blind, placebo controlled trial of inert
cellulose powder for the relief of symptoms of hay fever in adults.
Curr Med Res Opin 2006, 22:275–285.
13. Emberlin JC, Lewis RA: A double blind, placebo-controlled crossover trial
cellulose powder by nasal provocation with Der p1 and Der f1. Curr Med
Res Opin 2007, 23:2423–31.
doi:10.1186/1710-1492-9-32
Cite this article as: Ojeda et al.: A topical microemulsion for the
prevention of allergic rhinitis symptoms: results of a randomized,
controlled, double-blind, parallel group, multicentre, multinational
clinical trial (Nares study). Allergy, Asthma & Clinical Immunology 2013 9:32.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
